KEYNOTE-062: Pembrolizumab in HER2-, PD-L1  Positive Advanced Gastric Cancer

KEYNOTE-062: Pembrolizumab in HER2-, PD-L1 Positive Advanced Gastric Cancer

obr

4 months
174 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Thomas A. Abrams Senior Physician and Assistant Professor of Medicine at Harvard Medical School tells us his thoughts on KEYNOTE-62. This is investigating pembrolizumab in HER2, PD-L1 positive advanced gastroesophageal cancer.
Up Next Autoplay
Drug Resistance Found as Instestinal Tumor: How This Affects Clinicians
Drug Resistance Found as Instestinal Tumor: How This Affects Clinicians
Category: Gastrointestinal Cancer
4 Views
Massachusetts General Hospital 2 weeks
Cause of Drug Resistance Found in a Form of Intestinal Tumor
Cause of Drug Resistance Found in a Form of Intestinal Tumor
Category: Gastrointestinal Cancer
11 Views
Massachusetts General Hospital 2 weeks
Intestinal Tumor Commonly Asked Questions
Intestinal Tumor Commonly Asked Questions
Category: Gastrointestinal Cancer
4 Views
Massachusetts General Hospital 2 weeks
Drug Resistance Found As Intestinal Tumor
Drug Resistance Found As Intestinal Tumor
Category: Gastrointestinal Cancer
13 Views
Massachusetts General Hospital 2 weeks
When Do You Prescribe Bland Vs Chemo Or Radio Embolization: Chemo Embolization Has Not Caught On In Our Institution Because The Side Effects & Extra Months Of Durability Are Not Of Value
When Do You Prescribe Bland Vs Chemo Or Radio Embolization: Chemo Embolization Has Not Caught On In Our Institution Because The Side Effects & Extra Months Of Durability Are Not Of Value
Category: Gastrointestinal Cancer
217 Views
Annual-Meeting 5 months
Inducing Embolization Syndrome When Performing infarction: Not Uncommon To Take 4-8 Weeks To Get Over The Treatment Of Embolotherapy
Inducing Embolization Syndrome When Performing infarction: Not Uncommon To Take 4-8 Weeks To Get Over The Treatment Of Embolotherapy
Category: Gastrointestinal Cancer
26 Views
Annual-Meeting 5 months
Evaluating mTOR Inhibitor Everolimus With Embolotherapy: Objective Response Rate Of 57 We Did Not Stop Everolimus During Embolotherapy, We Continued It
Evaluating mTOR Inhibitor Everolimus With Embolotherapy: Objective Response Rate Of 57 We Did Not Stop Everolimus During Embolotherapy, We Continued It
Category: Gastrointestinal Cancer
126 Views
Annual-Meeting 5 months
Caring For Every Patient And Learning From Every Patient
Caring For Every Patient And Learning From Every Patient
Category: Gastrointestinal Cancer
159 Views
Annual-Meeting 5 months
The Quality and Completeness of Data
The Quality and Completeness of Data
Category: Gastrointestinal Cancer
114 Views
Annual-Meeting 5 months